Allergan (AGN) Tops Q3 EPS by 18c, Revenues Beat; Lifts FY18 Revenue Guidance Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Allergan (AGN) Tops Q3 EPS by 18c, Revenues Beat; Lifts FY18 Revenue Guidance Outlook
October 31, 2018 8:17 AM EDT
Credit Suisse analyst Vamil Divan lowered the price target on Allergen (NYSE: AGN) to $202.00 (from $213.00) while maintaining an Outperform rating.
Divan said the conference call highlighted new challenges. "The 3Q18 quarterly performance and 2018 guidance raise was somewhat expected, but comments around the outlook... More
October 29, 2018 9:30 AM EDT
Piper Jaffray analyst, Christopher Raymond, reiterated his Overweight rating on shares of Amgen (NASDAQ: AMGN) based on neurologist feedback on the current state of the migraine market. The analyst recently launched a new migraine survey targeting high volume migraine specialists (average 415 migraine patients under
management,... More
October 26, 2018 7:31 AM EDT
Allergan (NYSE: AGN) declared a quarterly dividend of $0.72 per share, or $2.88 annualized.
The dividend will be payable on December 14, 2018, to stockholders of record on November 13, 2018, with an ex-dividend date of November 9, 2018.
The annual yield on the dividend is 1.6 percent.
For a... More
